Aerie Pharma (AERI) Tops Q4 EPS by 176c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of $1.09, $1.76 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $32.7 million versus the consensus estimate of $31.45 million.

GUIDANCE:

Aerie Pharma sees FY2022 revenue of $130-140 million.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c